The three mammalian Raf serine/threonine protein kinases mediate the transduction of proliferative and differentiative signals from a variety of cell surface receptors to the nucleus. We report here that Craf-1 is essential for mouse development, as its mutation results in embryonic lethality. Developmental defects are found in mutant placentas as well as in the skin and in the lungs of mutant embryos. Craf-1 mutants also display a generalized growth retardation which is consistent with the ubiquitous expression of Craf-1 and which could be due to the reduced proliferation of mutant cells. Interestingly, the time-point of embryonal death varies depending on the genetic background. This suggests that Craf-1-mediated signaling is affected by genetic background-specific alleles of other genes.
Introduction
Extracellular stimuli are transmitted to nuclear transcription factors by signaling cascades made of protein kinases (Denhardt, 1996) . The best characterized of these cascades consists of three sequentially acting protein kinases, Raf, MEK and MAP kinase. This so-called Raf-MAP kinase pathway has been shown to control the expression of genes crucial for the physiological regulation of cell proliferation and differentiation (Daum et al., 1994) . Furthermore, oncogenic mutations in upstream activators of the pathway cause cell transformation and abnormal cell growth. For example, oncogenic mutations of Ras are found in nearly one-third of human cancers (Khosravi-Far and Der, 1994; Abrams et al., 1996) . Thus, an understanding of the regulation of this pathway at the molecular level is important for the development of therapeutic interventions for cancer and other disorders involving abnormal cell proliferation.
An important effector of Ras is the serine/threonine protein kinase Raf. Raf is thought indispensable for the acquisition of the transformed cell phenotype induced by oncogenic Ras (Kolch et al., 1991) . However, the understanding of Raf function in Ras signaling is complicated by the fact that in mammals both Ras and Raf are encoded by gene families rather than single genes. Gene families have evolved following duplications of an ancestral genome (Holland et al., 1994) , and limited predictions can be made about the function of the individual family members. The mammalian Raf family consists of three genes (Araf, Braf and Craf-1) which encode highly conserved proteins (Daum et al., 1994) . The homology between the Raf genes and their broad expression patterns suggest that they may possess overlapping functions. On the other hand, there is emerging evidence that the individual Raf isozymes may be differentially regulated by Ras and other upstream factors. For example, Araf and Craf-1, but not Braf, can be activated by Src (Marais et al., 1997) , whereas Braf and Craf-1 are differently regulated by cAMP (Erhardt et al., 1995) and NGF (Jaiswal et al., 1996) . Moreover, different Raf isozymes display different potencies in the activation of their substrates MEK and MAP kinase (Marais et al., 1997; Pritchard et al., 1995) . However, despite this considerable progress, the specific roles of the individual Raf isozymes remain unclear.
Identification of the specific function(s) of the individual Raf isozymes in mammalian development has recently been addressed by the generation of mouse strains with mutations in Raf genes. Araf-deficient mice display a variety of gastrointestinal and neurological defects including megacolon, abnormal movements, abnormal proprioception and excessive agitation. The phenotype undergoes modification by genetic regulators as evident by the variation in the postnatal lethality of Araf deficiency on different genetic backgrounds (Pritchard et al., 1996) . Braf-deficient mice die at mid-gestation of vascular defects caused by excessive cell death of endothelial cells (Wojnowski et al., 1997) . Both phenotypes also include growth retardation of embryos and newborn mice, respectively. This suggests that Araf and Braf participate in the development of a variety of tissues, while they are indispensable only for a restricted number of cell lineages.
In this paper we describe the phenotype of Craf-1-deficient mice. Disruption of Craf-1 results in embryonic lethality, indicating an essential role for this gene during mammalian development. However, the phenotype of Craf-1 mutants varies dramatically with the genetic background, suggesting that Craf-1-mediated signaling is affected by other gene products.
Results

Generation and biochemical analysis of Craf-1 mutant mice
The Craf-1 gene was disrupted by the introduction of a neo r gene into the first coding exon (exon 2) through homologous recombination in mouse strain 129-derived MPI II embryonic stem cells (Fig. 1A) . The mutation (designated Craf-1 neo2 ) was designed to delete the major translation initiation codon of Craf-1 which is localized in exon 2. Homologous recombination was identified in two out of 66 G418-and FIAU-selected ES cell clones by Southern blots (Fig. 1B) . Germline-transmitting chimaeras were obtained with both clones. Biochemical analysis of the effect of the mutation on Craf-1 protein was performed on wild-type, heterozygous and homozygous embryos and cells. As intended, the mutation abolished the expression of the 74 kDa wild-type Craf-1 protein in homozygous mice (Fig. 1C) . In lysates of Craf-1 neo2 /+ heterozygotes the amount of wild-type Craf-1 protein was reduced, indicating a gene-dosage effect.
The mutation also resulted in the expression of low levels (15% of the level of Craf-1 in wild-type cells) of an Nterminally truncated Craf-1 protein with an apparent size of 62 kDa (Fig. 1C) . Sequencing of the mutant Craf-1 mRNA revealed that the targeted exon 2 was spliced out ( Fig. 2A,B) . The size of the mutant Craf-1 protein suggests the utilization of a novel translation initiation site in exon 3. Exon 3 contains two potential translation initiation sites ( Fig. 2A,B ) and the predicted weight of the truncated proteins (65 kDa and 64 kDa, respectively) is similar to the 62 kDa estimated by SDS-PAGE. The kinase activity of the 62 kDa mutant Craf-1 was investigated in fibroblasts derived from wild-type and Craf-1 neo2/neo2 homozygous embryos. Serum-starved cells were stimulated with the activators of Craf-1 kinase, epidermal growth factor (EGF), fetal calf serum (FCS), and phorbol myristate acetate (PMA). Following stimulation and cell lysis, Craf-1 was immunoprecipitated and its activity tested in a coupled kinase assay with recombinant MEK1, MAP kinase, and [ 32 P]ATP. As shown in Fig. 2C , the 62 kDa Craf-1 protein had no detectable kinase activity in non-stimulated homozygous mutant fibroblasts. However, some residual kinase activity of the 62 kDa Craf-1 was detected following the stimulation with FCS and PMA. This activity was equal to 10% of the activity of 74 kDa Craf-1 immunoprecipitated from an equivalent amount of lysate of wild-type fibroblasts.
We also wanted to determine if the 62 kDa Craf-1 had a dominant-negative effect on the activation of MAP kinase mediated by pathways independent from Craf-1. Lysates of wild-type and homozygous mutant fibroblasts stimulated with EGF, FCS and PMA were resolved on an SDS-PAGE gel, blotted, and probed with a polyclonal antibody which recognizes dually phosphorylated, activated MAP kinase. No differences in the activation of MAP kinase were found between wild-type and homozygous mutant fibroblasts ( Fig. 2D) , indicating that the truncated protein does not have dominant-negative effect. Taken together, the data show that the introduced mutation abolishes the expression of wild-type Craf-1 protein, but results in the expression of an aberrant 62 kDa Craf-1 protein with residual kinase activity.
The Craf-1 mutant phenotype is dependent on the genetic background
Germ-line chimeras were bred to 129, C57Bl/6 and CD1 females to assess the phenotype on inbred and outbred genetic backgrounds. Heterozygous animals displayed no obvious anatomical or behavioral abnormalities, increased mortality, or tumor formation over a period of 12 months. However, no viable homozygous mutant mice were found among offspring from intercrosses between heterozygous parents on any genetic background (Ͼ100 offspring genotyped for each background), indicating a recessive embryonal lethal phenotype. To determine the time-course of the lethality, we dissected embryos from such intercrosses at different stages of gestation. Homozygous embryos were recovered at the expected Mendelian frequencies on all backgrounds tested until E10.5, indicating that the mutation had no effect on implantation. Surprisingly, we found a marked variability in the onset of embryonic lethality in the different genetic backgrounds. Thus, 96% of homozygous mutant embryos on the inbred backgrounds C57Bl/6 (F2 generation) and 129 died between E10.5 and E12.5 (Fig.  3A) . In contrast, on the outbred background CD1 56% and 87% of homozygous mutants were alive at E12.5 in the F2 and F3 generations, respectively (Fig. 3A) . The number of viable homozygous mutants on CD1 background (F3 generation) decreased with gestational age, but two-thirds reached term, then died within hours after birth (Fig. 3C ). These results show that Craf-1 is essential during mouse embryogenesis, but its function undergoes strong modification by genetic background-specific alleles of other genes.
Developmental delay and growth retardation of Craf-1 mutants
Craf-1 neo2/neo2 mutant embryos on the inbred 129 or mixed 129/C57Bl/6 genetic backgrounds failed to develop beyond mid-gestation. Those mutant embryos that were still alive at E10.5 (as judged by the presence of a regular heartbeat), were much smaller than their littermates and appeared to be developmentally arrested. A typical example is shown in Fig. 3B . The developmental arrest was particularly pronounced in the posterior region of the homozygous embryos, which often failed to complete axial rotation. Many embryos also exhibited a distended pericardium and irregular folding of the neural tube. On the outbred CD1 background (F3 generation), growth retardation was detectable first at E12.5, and the weight gap between mutant homozygous and non-homozygous embryos increased Asterisks indicate the physiological, and the potential translation initiation sites in exon 2 and 3, respectively. (C) Kinase activity of the 74 kDa wildtype, and the 62 kDa mutant, Craf-1 proteins, in untreated cells (U) and after stimulation with epidermal growth factor (E), fetal calf serum (F), and phorbol myristate acetate (P).
32 P-MAPK, phosphorylated MAP kinase; yP-MAPK, tyrosine-phosphorylated MAP kinase; HC, heavy chain. (D) Phosphorylation of MAP kinase in whole-cell lysates following stimulation of cells with epidermal growth factor (E), fetal calf serum (F), and phorbol myristate acetate (P).
with the age of embryos. The weight of the oldest surviving mutants (E18.5) was reduced by one-third and they could be easily distinguished from non-homozygous littermates (Fig.  3D) . The weight deficiency at E18.5 was equivalent to a developmental delay by 1 to 1.5 gestational days (Kaufman, 1992) (Fig. 4A) . A delay of similar extent was also observed in the skeletal system of mutants on the CD1 genetic background, as evidenced by the absence of the ossification centers appropriate for this stage (Kaufman, 1992) (Fig.  3E,F) .
Since growth deficiency can be caused by a defective function of extraembryonal structures such as placenta (Copp, 1995) , we examined mutant and wild-type placentas on the CD1 genetic background (F3 generation). We observed an arrest in growth of mutant placentas beginning at E10.5 (Fig. 4B) . Histological examination showed that the spongiotrophoblast and the labyrinth layers of mutant placentas were reduced in size whereas the giant cell layer appeared normal (Fig. 5A ). The mutant spongiotrophoblast had a less spongy appearance than in the controls. The number of cytotrophoblast cells and blood vessels in the labyrinth layer was reduced (Fig. 5B) . Instead, the labyrinth layer contained large numbers of poorly differentiated mesenchymal cells. These defects are likely to affect the placenta's ability to meet the demands of the embryo during its progressive growth. 
Organ defects in Craf-1 mutants
Despite the generalized growth deficiency, most of the mutant tissues appeared normal. Specific abnormalities were found in the skin, in the fusion of the eyelids, and in the lungs of Craf-1 neo2/neo2 mutants (Fig. 6) . Skin defects were found in the dermal and epidermal layers, both of which were thinner and less differentiated than normal (Fig. 6A) . Within the epidermis, the layers were poorly differentiated and the keratinization of the stratum corneum Fig. 4 . Growth deficiency of Craf-1 neo2/neo2 homozygous embryos (A) and placentas (B) on the CD1 genetic background (F3 generation). Delayed growth of mutant embryos is detectable beginning at E12.5 and it is equivalent to one day delay in development (dashed line in B) at E18.5. Note the lack of growth of mutant placentas beyond E10.5. Embryonic and placental weights were determined in embryos that were alive at the time of dissection. Data represent mean values ± SD of 3-11 embryos/placentas for each point. was reduced. The hair follicles were much smaller and less well developed in newborn mutants (Fig. 6A) , although their number and orientation were similar to those of wild-type littermates (not shown).
Normally, mouse pups are born with closed eyes due to fusion of the eyelids at E16, and eyes open again around day 13 of postnatal life (Kaufman, 1992) . In contrast, forty percent of E18.5 and older Craf-1 neo2/neo2 pups had open eyes as illustrated in Fig. 6B . To determine whether the structure of the eye was otherwise affected in the mutants, we examined sections through heads of several mutants. In one out of four mutants with open eyelids (E17.5-P0) we found a folding of the retina, whereas no such defect was detected in mutants with fused eyelids or in normal littermates (Fig. 6C ). This suggests that the failure of eyelid fusion may be accompanied by other eye defects with low penetrance.
Craf-1 neo2/neo2 mutants died shortly after birth and most of them were partly cannibalized despite frequent monitoring. We have therefore delivered several E19.5 litters from matings between mutant heterozygotes. Craf-1 neo2/neo2 mutant pups from these litters exhibited normal breathing reflexes, but their lungs failed to inflate, as evidenced by histological analysis. Mutant lungs were smaller when compared to the corresponding sections of wild-type littermates. The size reduction resulted from hypoplasia of parenchymal cells in alveolar septa, whereas the number of air spaces was similar in mutant and control embryos (Fig. 6D) . The defective structure of the lungs was the likely cause of death in mutants that survived to term.
Reduced proliferation in Craf-1 mutant fibroblasts
The analysis of signal transduction pathways would greatly benefit from the availability of cell lines defective in Craf-1 kinase activity. As a first step, we have established primary cultures of mutant and wild-type E14.5 mouse embryonic fibroblasts. Mutant and wild-type cells exhibited the same flattened morphology and contact-inhibited growth that is characteristic of untransformed fibroblasts. However, homozygous mutant fibroblasts appeared to grow more slowly compared to wild-type cells. We therefore measured cell proliferation in serum-starved cells and after stimulation with fetal calf serum (FCS). As expected, stimulation with FCS led to a concentration-dependent increase in BrdU incorporation in both wild-type and homozygous mutant cells (Fig. 7) . However, the BrdU incorporation in mutant cells was one-half that of wild-type cells at all FCS concentrations tested, indicating a reduced proliferation rate.
Discussion
The mammalian Raf family consists of three highly homologous genes but most studies have focused on the functions of Craf-1. Craf-1 was the first Raf discovered (Mark and Rapp, 1984) and it continues to be the best characterized member of the mammalian Raf family. We have generated a mutant allele of Craf-1 in the mouse and analyzed its function during embryogenesis. Our results show that Craf-1 is essential for normal mouse development since disruption of the gene leads to embryonic or perinatal death.
The phenotype of the Craf-1 deficiency is strikingly dependent on the genetic background. On an inbred 129 or mixed 129/C57Bl/6 genetic background, mutant embryos appeared developmentally arrested during early organogenesis. This finding points to a critical role of Craf-1 during early organogenesis, a period of rapid embryonic growth. In contrast, when the Craf-1 mutation was introduced into an outbred CD1 background, only a small fraction of embryos died during early organogenesis. On this genetic background, most mutants survive until birth and die immediately afterwards, most likely due to the immaturity of the lungs and the skin. These results strongly suggest the presence of (a) genetic modifier(s) in CD1 mice that can partially compensate for the Craf-1 deficiency. Their identity is at present unknown, but they could be components of pathways that are functionally redundant with Craf-1. The identification of these modifier loci through linkage analysis should be feasible. The observation that Craf-1 signaling is strongly influenced by the genetic background also has important implication for the interpretation of previous studies concerning Craf-1 function, most of which have been done in genetically undefined systems.
Craf-1 mutant exhibit specific defects of the skin, of the lungs and of the eyelid closure. The lack of eyelid closure at E19.5 is equivalent to a development delay by 2.5-3.5 days (Kaufman, 1992) and it clearly exceeds the growth delay of the mutants at this stage (1-1.5 days). Similar skin, lung and eyelid defects, accompanied by a general growth retardation, and a strong dependency of the phenotype on the genetic background, have been observed in EGF receptor mutants (Sibilia and Wagner, 1995; Threadgill et al., 1995) . These similarities suggest that Craf-1 may be particularly important in the transmission of signals from EGF receptor in the mouse, and it is in agreement with genetic studies in Drosophila (Brand and Perrimon, 1994) . The open eye phenotype observed in 40% of Craf-1 neo2/neo2 embryos on the CD1 background has also been reported in mice mutant for the activator of Craf-1 (Zou et al., 1997 ), c-Abl (Schwartzberg et al., 1991 , as well as in TGF-a (Luetteke et al., 1993) , and Activin (Vassalli et al., 1994 ) mutant mice. The growth retardation of mutant embryos could be fully explained by placental defects. However, the reduced proliferation of mutant cells may also have contributed to this phenotype. Previous biochemical studies have implicated Craf-1 in the transmission of mitogenic signals (Kolch et al., 1991) and our results are in agreement with these observations. While disruption of Craf-1 had no arresting effect on cell proliferation, our analysis could represent an underestimate of the role of Craf-1 in cell proliferation, due to the presence of low levels of a truncated Craf-1 protein. The availability of cell lines deficient in Craf-1 and in the other Raf isozymes should aid efforts to develop cancer therapy based on the inhibition of function of the oncogenic Ras. Ras is mutated in 30% of human cancers (Abrams et al., 1996; Khosravi-Far and Der, 1994) and its transforming potential is dependent on Raf (Kolch et al., 1991) . The small size of the binding interface between Ras and Raf makes this signaling node an attractive target for cancer therapies (Nassar et al., 1995) .
Independent of the genetic background, disruption of Craf-1 has no lethal effect on mutant embryos until E10.5. This observation was surprising, considering previous studies with overexpression of dominant-negative and constitutively-active versions of Craf-1 and its activator Ras. Ras/ Raf signaling has been reported to be indispensable for the progression of mouse embryos through the two-cell stage, albeit to be dispensable for the subsequent development to morulae and blastocysts (Yamauchi et al., 1994) . Injections of animal cap explants with a dominant-negative Craf-1 mutant has revealed its essential role in the induction of mesoderm in Xenopus (MacNicol et al., 1993) . It is possible that Araf, Braf and Craf-1 are functionally redundant during early mammalian development. Such redundancies are frequent among homologous proteins as has been demonstrated for the families of Raf regulators, Ras (Johnson et al., 1997) , and GAP (Henkemeyer et al., 1995) . On the other hand, it is conceivable that the residual activity of the truncated 62 kDa Craf-1 is sufficient to transmit growth and differentiation signals until mid-gestation. Analysis of mouse embryos mutant for multiple Raf genes will be necessary to elucidate functional redundancies among Raf proteins.
Materials and methods
Targeting vector and genotyping
Two overlapping genomic clones encompassing the second and third exon of murine Craf-1 were isolated from a 129 lambda FIX library (Stratagene) and their identity was confirmed by nucleotide sequencing. In the targeting vector, a neomycin resistance cassette, flanked by 6.8 kbp of genomic DNA, replaces the coding portion of the second exon. The linearized vector was electroporated into the 129Sv/ Pas-derived MPI II ES cells (gift from A. Voss and P. Gruss), and colonies were isolated following G418 and FIAU selection (Mansour et al., 1988) . Targeted clones (two out of 69) were identified by Southern hybridization as shown in Fig. 1B . Germline-transmitting chimaeras were mated to CD1, C57Bl/6, and 129SvEms mice. Genotyping of embryos was performed on DNAs isolated from yolk sacs or embryos by Southern hybridization and/or PCR (Fig.  1B,C) . The primers for PCR were: Craf-R, 5′-GGG ATT CTG GGA GTT TGG GGC CAG CAG CTA; Neo-L, 5′-AGT GCC AGC GGG GCT GCT AAA; and C2-2, 5′-CAC AGT CCT TTG CTT ATT CGG. The sequence of Craf-R is derived from the first intron of Craf-1 gene. The sequence of primer C2-2 is derived from the second exon of Craf-1 gene and it is deleted in the targeted allele. The sequence of Neo-L is derived from the neomycin cassette. Primers Craf-R and C2-2 amplify a ∼300 bp fragment of the wild-type allele, whereas Craf-R and Neo-L amplify a ∼200 bp fragment of the targeted allele.
Biochemical analysis
The mRNA encoding the mutant 62 kDa Craf-1 protein was analyzed by RT-PCR and sequencing. Total RNA isolated from homozygous mutant or wild-type fibroblasts was reverse-transcribed, and the 5′ portion of Craf-1 was amplified using primers mC1F3 (5′ ACC AAC GCG TTC TCT CAA CCA 3′) and C4-2 (5′ AAA GTT GTG AGT TGT GAT GGG 3′) which are derived from the first and fourth exon of murine Craf-1, respectively. The kinase assays were performed as previously described (Stancato et al., 1997) on embryonic fibroblasts derived from E14.5 wild-type and homozygous mutant littermates. Briefly, confluent cells were serum-starved for 24 h and then stimulated for 10 min with 60 ng/ml epidermal growth factor, 20% fetal calf serum, or 500 ng/ml phorbol myristate acetate. Following the stimulation, cells were lysed in a Triton X-100-containing buffer. Craf-1 was immunoprecipitated with a rabbit polyclonal Craf-1 antibody (Santa Cruz Biotechnology, cat. no. sc-133-G). Kinase assays were performed in the presence of recombinant MEK1, MAP kinase, and [ 32 P]ATP. Samples were resolved by SDS-PAGE, transferred to a nitrocellulose membrane, and the phosphorylation of the MAP kinase was quantitated using a PhosphorImager and densitometry analysis. The amount of Craf-1 was determined by probing the same membrane with a mouse monoclonal Craf-1 antibody (Transduction Laboratories, cat. no. R19120), followed by a 125 I-labeled goat anti-mouse IgG. To determine Craf-1-independent phosphorylation of MAP kinase, clarified whole-cell lysates (10 mg of protein) were resolved by SDS-PAGE, transferred to a nitrocellulose membrane, and probed with a rabbit polyclonal antibody (Promega, cat. no. V6671) which recognizes dually phosphorylated, activated MAP kinase. The proliferation rate of wild-type and homozygous mutant embryonic fibroblasts (E14.5, CD1 background, F3 generation) was estimated by measuring the incorporation of 5-bromo-2′-deoxyuridine (BrdU). Cells were plated in 0.2% FCS in DMEM onto 96-well plates to achieve ≈ 30% confluency and allowed to attach overnight. Subsequently, the cells were stimulated with 0.63-10% FCS for 24 h, and then for additional 6 h in the presence of 10 mM BrdU. Afterwards the cells were fixed and the BrdU incorporation was determined colorimetrically following an immunoassay (Cell proliferation ELISA, Boehringer).
Embryo analysis
For general histology, dissected embryos were fixed in 4% paraformaldehyde/1 × PBS, embedded in wax, sectioned, and counterstained with hematoxylin/eosin. Embryonal and placental weights were determined in embryos and placentas fixed in 4% paraformaldehyde/ 1 × PBS and stored in 70% ethanol. For skeletal analysis, embryos were eviscerated, fixed in ethanol, and stained with alizarin red and alcian blue as described previously (McLeod, 1980) . The embryos were then cleared with 1% KOH and stored in glycerol.
